 |
|
Treatment of Pyoderma Gangrenosum With Cyclosporine
Wendy L. Matis, MD;
Charles N. Ellis, MD;
Christopher E. M. Griffiths, MB, MRCP;
Gerald S. Lazarus, MD
Arch Dermatol. 1992;128(8):1060-1064.
Abstract
• Background and Design.—
Pyoderma gangrenosum is a chronic inflammatory ulcerative skin disease of unknown origin, often associated with various diseases including inflammatory bowel disease, inflammatory arthritis, monoclonal gammopathies, hepatitis, and myeloproliferative disorders. Treatment of associated systemic disorders may improve the ulcers, but lesions may be recalcitrant and persist for months to years. Therapy for pyoderma gangrenosum includes high-dose systemic corticosteroids, sulfa drugs such as sulfasalazine, clofazimine, and immunosuppressive agents such as mercaptopurine and azathioprine; these drugs are sometimes ineffective.
Results.—
We present a series of 11 patients with pyoderma gangrenosum, with a wide range of underlying diseases, whose ulcers were refractory to usual therapy and who were treated with low-dose cyclosporine. Ten of the 11 patients cleared rapidly and completely with cyclosporine therapy.
Conclusions.—
Cyclosporine should be seriously considered as a primary form of treatment for pyoderma gangrenosum.
(Arch Dermatol. 1992;128:1060-1064)
Author Affiliations
From the Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia (Drs Matis and Lazarus); and the Department of Dermatology, University of Michigan Medical Center, Ann Arbor (Drs Ellis and Griffiths).
Footnotes
Accepted for publication February 7, 1992.
Presented in a poster at the Society of Investigative Dermatology meeting, Seattle, Wash, May 2, 1991.
Reprint requests to the Department of Dermatology, University of Pennsylvania, 211 Clinical Research Bldg, 422 Curie Blvd, Philadelphia, PA 19104 (Dr Lazarus).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
European evidence based consensus on the diagnosis and management of Crohn's disease: special situations
Caprilli et al.
Gut 2006;55:i36-i58.
ABSTRACT
| FULL TEXT
Important cutaneous manifestations of inflammatory bowel disease
Trost and McDonnell
Postgrad. Med. J. 2005;81:580-585.
ABSTRACT
| FULL TEXT
The Effectiveness of Mycophenolate Mofetil in Refractory Pyoderma Gangrenosum
Nousari et al.
Arch Dermatol 1998;134:1509-1511.
FULL TEXT
Peristomal Pyoderma Gangrenosum and Inflammatory Bowel Disease
Cairns et al.
Arch Surg 1994;129:769-772.
ABSTRACT
|
